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I. PROJECT ID NUMBER, PUBLICATION  MORATORIUM INFORMATION, 
PROJECT DESCRIPTION:
This manuscript is part of a pilot effort on the part of NHI staff and the Nature publishing group 
to provide a more convenient archive for "marker papers" to be published.  These "marker 
papers" are designed to provide the users of community resource data sets with information 
regarding the status and scope of individual community resource projects.  For further 
information see editorial in September 2010 edition of Nature Genetics (Nature Genetics, 42, 
729 (2010)), and the Nature Proceedings HMP summary page.
The data has been deposited in NCBI with the following project ID number 46337.  There is a 
one year publication moratorium on all data other than DNA sequence data from this study 
starting from the time of data submission.  There is no publication moratorium on DNA 
sequence data from this study. 
  
Necrotizing enterocolitis (NEC) is a devastating disorder that affects approximately 10% of 
premature infants. Its mortality remains high (15-30%), and its cause remains unknown. About 
80% of cases occur within 35 days of birth among hospitalized newborns of low birth weight. 
Probiotics diminish the incidence and severity of NEC, and NEC does not occur antepartum. 
NEC affects a readily identifiable at-risk group, has a tightly defined interval before its onset, 
occurs in an organ system that is intimately associated with a microbial population in flux, has a 
plausible association with the intestinal microbiota, and cohorts at risk have rarely been studied 
in large numbers, or prospectively. This disorder, therefore, provides a unique opportunity to 
explore the role of the human enteric microbiome in a devastating disease. Moreover, NEC 
epidemiology and age-incidence present an ability to enroll and study cohorts that are highly 
likely to provide valuable pathophysiologic and microbiologic insights.
In this project, we will identify and quantify the microbial components of stool and its products 
before and at the onset of NEC. In doing so, we will test the overarching hypothesis that NEC 



































multicenter cohorts of premature infants at high risk of developing NEC, extend our research on 
this disease currently sponsored by the Washington University Institute of Clinical and 
Translational Sciences, and continue our longstanding collaborations with the Genome Center at 
Washington University and the Washington University Digestive Diseases Research Core Center 
(Informatics Core). The Aims of this proposal are to (1) conduct a case cohort study in which we 
compare clinical data and biological specimens from cases and well-matched controls; (2) 
determine if the kind and density of intestinal biomass, its gene content, and transcriptional 
activity are associated with, and potential determinants of, NEC; and (3) determine if host risk 
alleles for intestinal inflammation play a role in the development of NEC. These efforts will be 
accomplished using subjects from three collaborating neonatal intensive care units (NICUs), 
focusing on the critical, instructive, and understudied pre-NEC stage of illness, and formulating a 
data repository that will be a resource for investigators worldwide who wish to focus their efforts 
on NEC, its precipitants, and its prevention and cure.
II. DATA QUALITY: 
The quality of capillary sequencing data (Sanger sequencing on the AB3730 instrument) at the 
Genome Center at Washington University is measured by assessing the failure rate of each 
individual set of 96 lanes within one full run.  Within each run these failures are samples with no 
data or samples that have fewer than 20 high quality bases.  A high quality base is one with a 
quality score greater than phred Q20. The number of such failed samples is noted for each run. 
Successful runs are those with fewer than 20% failures, although this number is often set more 
stringently. 
In addition, the overall read length for all passing samples is measured across many different 
variables (e.g. high quality bases) to make sure that it says within the standard expected for this 
platform.  The expected read length at this time is 700 bases of a quality score greater than  phred 
Q20.
The Illumina production pipeline is evaluated by the number of passing reads that contain high 
quality data.  The Illumina software on the instrument calculates the number of passing reads as 
well as the number of clusters (a cluster is formed from a single DNA fragment) that might 
produce data.  The reports also offer information regarding the phasing or the ability of the 
instrument to stay in step with each base that is called.  In addition to this, when possible, the 
error rate is evaluated by evaluation of an internal standard of known sequence or by alignment 
of the experimental sequences to known reference sequences, when available. Successful runs 
are those producing an expected full set of reads with a low error rate. The full set of reads 
depends on the sequencing conditions while error rates are typically < 1%, analogous to phred 
Q20.
Sequencing on the Roche-454 platform is similarly evaluated by the number of reads and bases 



































In addition, we have instituted a barcode specimen tracking system to increase our ability to 
monitor specimens as they are processed, stored, and distributed throughout the project. 
III. DATA ANALYSIS AND PUBLICATION PLANS:  
Our data analysis objectives are to report on the kinetics, and to characterize in depth, the enteric 
microbiota in the premature infant at risk for NEC.  Publications concerning methodology and 
the descriptive ecology of this biomass are published, submitted, or in preparation.  Additional 
publications, to be submitted at a rate of approximately two per annum, will focus on bacteria 
present, the genes they contain, the transcripts they contain, the host response to this biomass, 
and technological validations and methodologic assessments.
IV. DATA RELEASE PLAN:  
The GCWU plans to release the sequence reads to the NCBI Trace Archive without delay and 
has a data submission pipeline in place that has been doing this for years. We are releasing our 
16S and whole genome shotgun metagenomic data to SRA. We will also release genome 
assemblies without delay, although the NIAID policy allows for a brief delay. Again, we have a 
pipeline in place that has routinely submitted assemblies and annotations to GenBank and 
worked with them to resolve discrepancies. We are releasing disease phenotype data linked to 
microbiome data to controlled access dbGaP. The PI should be contacted if there is an interest in 
accessing the dbGaP controlled access data.
V. CONTACT PERSON: 
Dr. Phillip I. Tarr, Washington University, tarr@kids.wustl.edu
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